Thyroid-stimulating hormone receptor gene mutations and polymorphisms in thyroid disease

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 5, 1996, Pages 428-432

  Russo, Diego ^a   Arturi, Franco ^a   Filetti, Sebastiano ^a  

^a UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008163831     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199610000-00012     Document Type: Article

References (45)

1. Nagayama Y, Rapoport B: The thyrotropin receptor 25 years after its discovery: new insight after its molecular cloning. Mol Endocrinol 1992,6:145-156.
2. Vassart G, Parma J, van Sande J, Dumont JE: The thyrotropin receptor and the regulation of thyrocyte function and growth: update 1994. Endocr Rev 1994, 3:77-80.
3. Dumont JE, Lamy F, Roger P, Maenhaut C: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992, 72:667-697.
4. Laugwitz K-L, Allgeier A, Offermann S, Spicher K, van Sande J, Dumont JE, Schultz G: The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci U S A 1996, 93:116-120. This study suggests that the activated human TSHR can couple to at least 10 different G proteins.
5. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh Q-Y, Clark OH, Kawasaki E, Bourne HR, McCormick F: Two G protein oncogenes in human endocrine tumors. Science 1990, 249:655-659.
6. Weinstein LS, Shenker A: G protein mutations in human disease. Clin Biochem 1993, 26:333-338.
7. Pearce SHS, Trump D: G-protein-coupled receptors in endocrine disease. Q J Med 1995, 88:3-8.
8. Parma J, Duprez L, van Sande J, Cochaux P, Gervy G, Mockel J, Dumont JE, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
9. O'Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR: Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991, 4:345-349.
10. Saïd S, Schlumberger M, Suarez HG: Oncogenes and antioncogenes in human epithelial thyroid tumors. J Endocrinol Invest 1994, 17:371-379.
11. Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE: Novel mutations of thyrotropin receptor in thyroid hyperfunctioning adenomas: rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 1994, 79:657-661.
12. Paschke R, Tonacchera M, van Sande J, Parma J, Vassart G: Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab 1994, 79:1785-1789.
13. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, duVillard JAD, Caillou B, Monier R, Rapoport B, Filetti S, Suarez HG: Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995, 80:1347-1351. Includes a comprehensive study of the TSHR gene, gsp, and ras gene mutations in 37 thyroid hyperfunctioning adenomas. The study is unique because all three genes are examined in each sample. Mutations were not found simultaneously in any sample, suggesting that each gene can play an independent role in the development of hyperfunctioning thyroid adenomas.
14. Takeshita A, Nagayama Y, Yokoyama N, Ishikawa N, Ito K, Yamashita T, Obara T, Murakami Y, Kuma K, Takamatsu J, Ohsawa N, Nagataki S: Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab 1995, 80:2607-2611. Shows a low frequency of TSHR gene mutations in hyperfunctioning thyroid adenomas in Japan. One possible explanation of this finding may be a geographic variation because Japan is a relatively iodine-sufficient area compared with Europe.
15. 2+ cascades. Mol Endocrinol 1995, 9:725-733. This is the first study in which the entirety of exon 10 of the TSHR gene was examined in 11 hyperfunctioning thyroid adenomas. Activating mutations have been identified in about 80% of toxic adenomas. In two cases the researchers were able to constitutively activate both the regulatory cascades normally under the control of TSH.
16. Russo D, Arturi F, Suarez HG, Schlumberger M, duVillard JAD, Crocetti U, Filetti S: Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996, 81:1548-1551. The entirety of exon 10 of the TSHR gene was examined in 44 hyperfunctioning thyroid adenomas. Somatic mutations of the TSHR gene, responsible for the constitutive activation of the cAMP cascade, were found in 20% of the tumors.
17. Gross B, Misrahi M, Sar S, Milgrom E: Composite structure of the human thyrotropin receptor gene. Biochem Biophys Res Commun 1991, 177:679-687.
18. van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart G: Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995, 80:2577-2585. Reports a comparative analysis of the functional characteristics of 11 constitutively active TSHR mutants following transfection in COS-7 cells. Both pathways-cAMP and inositolphosphate cascades-were examined.
19. Strader CD, Fong TM, Tota MR, Underwood D: Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994, 63:101-132.
20. Chazenbalk GD, Nagayama Y, Russo D, Wadsworth HL, Rapoport B: Functional analysis of the cytoplasmic domains of the human thyrotropin receptor by site-directed mutagenesis. J Biol Chem 1990, 265:20970-20975.
21. Bertherat J, Chanson P, Montminy M: The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995, 9:777-783. Reports the presence of activated CREB protein in a series of pituitary adenomas activated independently by the presence of a gsp mutation. This suggests the involvement, in the gsp-negative samples, of other elements of the cAMP cascade. Because of the close analogy between thyroid and pituitary hyperfunctioning tumors, the same hypothesis can be postulated for thyroid pathologies.
22. Suarez HG, duVillard JA, Caillou B, Schlumberger M, Parmentier C, Monier R: gsp Mutations in human thyroid tumours. Oncogens 1991, 6:677-679.
23. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M: Rare mutations of the Gs alpha subunit in human endocrine tumors. Cancer 1993, 72:1386-1393.
24. Horie H, Yokogoshi Y, Tsuyuguchi M, Saito S: Point mutations of ras and Gsα subunit genes in thyroid tumors. Jpn J Cancer Res 1995, 86:737-742.
25. Matsuo K, Friedman E, Gejman PV, Fagin JA: The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the a-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab 1993, 76:1446-1451.
26. Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, Filetti S, Suarez HG: Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 1995, 11:1907-1911. Provides the first evidence of activating mutations of the TSHR gene in differentiated thyroid carcinomas. The mutations were found in a series of carcinomas selected for their constitutive high adenlyl cyclase activity. In one tumor the simultaneous presence of a TSHR gene mutation and N-ras mutation has been identified.
27. Ohno M, Endo T, Ohta K, Gunji K, Onaya T: Point mutations in the thyrotropin receptor in human thyroid tumors. Thyroid 1995, 5:97-100.
28. Wynford-Thomas D: Molecular genetics of thyroid cancer. Curr Opin Endocrinol Diabetes 1995, 2:429-436.
29. Michiels F, Caillou B, Talbot M, Dessarps-Freichey F, Maunaury M, Schlumberger M, Merken L, Monier R: Oncogenic potential of guanine nucleotide stimulatory factor: a subunit in thyroid gland of transgenic mice. Proc Natl Acad Sci U S A 1994, 91:10488-10492.
30. Ledent C, Dumont JE, Vassart G, Parmentier M: Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J 1992, 11:537-542.
31. Duprez L, Parma J, van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle M-J, Decoulx M, Orgiazzi J, Dumont JE, Vassart G: Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994, 7:396-401.
32. Tonacchera M, van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J: Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996, 81:547-554.
33. Kopp P, van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G: Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995, 332:150-154.
34. Sunthornthepvarakul T, Gottschalk ME, Hayashi Y, Refetoff S: Brief report: resistance to thyrotropin caused by mutation in the thyrotropin receptor gene. N Engl J Med 1995, 332:155-160.
35. Takeshita A, Nagayama Y, Yamashita S, Takamatsu J, Ohsawa N, Maesaka H, Tachibana K, Tokuhiro E, Ashizawa K, Yokoyama N, Nagatakai S: Sequence analysis of the thyrotropin (TSH) receptor gene in congenital primary hypothyroidism associated with TSH unresponsiveness. Thyroid 1994, 4:255-259.
36. Bohr URM, Behr M, Loos U: A heritable point mutation in an extra-cellular domain of the TSH receptor involved in the interaction with Graves' immunoglobulins. Biochim Biophys Acta 1993, 1216:504-508.
37. Bahn RS, Dutton CM, Heufelder AE, Sarkar G: A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994, 78:256-260.
38. Sunthornthepvarakul T, Hayasahi Y, Refetoff S: Polymorphism of a variant human thyrotropin receptor (hTSHR) gene. Thyroid 1994, 4:147-149.
39. Cuddihy RM, Dutton CM, Bahn RS: A polymorphism in the extracellular domain of the thyrotropin receptor is highly associated with autoimmune thyroid disease in females. Thyroid 1995, 5:89-95.
40. Leos U, Hagner S, Bohr URM, Bogatkewitsch GS, Jakobs KH, van Koppen CJ: Enhanced cAMP accumulation by the human thyrotropin receptor variant with the Pro52Thr substitution in the extracellular domain. Eur J Biochem 1995, 232:62-65.
41. Cuddihy RM, Bryant PW, Bahn RS: Normal function in vivo of a homozygotic polymorphism in the human thyrotropin receptor. Thyroid 1995, 4:255-257.
42. Watson PF, French A, Pickerill P, McIntosh S, Weetman AP: Lack of association between a polymorphism in the coding region of the thyrotropin receptor gene and Graves' disease. J Clin Endocrinol Metab 1995, 80:1032-1035.
43. Nagayama Y, Kaufman KD, Selo P, Rapoport B: Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun 1989, 165:1184-1190.
44. Libert F, Lefort A, Gerard C, Parmentier M, Perret J, Ludgate M, Dumont J, Vassart G: Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 1989, 165:1250-1255.
45. Misrahi M, Loosfelt H, Atger M, Sar S, Guiochon-Mantel A, Milgrom E: Cloning, sequencing and expression of human TSH receptor. Biochem Biophys Res Commun 1990, 166:394-403.